{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:07Z","timestamp":1792616347491,"version":"4.5.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin (IL)-17 inhibitor is a biological therapy approved for moderate to severe psoriasis and psoriatic arthritis. The common adverse events of IL-17 inhibitor include injection site reaction, infections, nasopharyngitis, and headache. However, vitiligo associated with the use of IL-17 inhibitors was rarely reported in the previous literature. Here we described a woman who developed <jats:italic>de novo<\/jats:italic> vitiligo after 4 months of IL-17A inhibitor treatment for psoriasis and psoriatic arthritis. Upon discontinuation of IL-17A inhibitor and shifting to a broader T cell inhibitor\u2014cyclosporine, our patient had control of both psoriasis and vitiligo and achieved 75% repigmentation after 3 months of oral cyclosporine without phototherapy. Due to the increasing use of anti-IL-17 biologics in psoriasis patients, clinicians should inquire about vitiligo\u2019s history before treatment and inform patients of the possible adverse effects.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1077681","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T05:53:32Z","timestamp":1674021212000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Hsing-Jou","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Pei","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Chieh","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lung","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau Yee","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: A systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02905.x","article-title":"Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18","volume":"126","author":"Darwich","year":"2009","journal-title":"Immunology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000510831","article-title":"Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: A case report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"B9","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.4.2004","article-title":"The source of early IFN-gamma that plays a role in Th1 priming","volume":"167","author":"Das","year":"2001","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: A review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0394-1","article-title":"Association between psoriasis and vitiligo: A systematic review and meta-analysis","volume":"20","author":"Yen","year":"2019","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1077681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T05:53:35Z","timestamp":1674021215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1077681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.1077681"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1077681","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"article-number":"1077681"}}